When Merck & Co. pulled Vioxx from pharmacy shelves worldwide on 30 September 2004, chief executive Raymond Gilmartin framed it as a responsible company acting on new data; the documented record shows a five-year gap between that posture and what the company’s own clinicians had measured. Vioxx (rofecoxib), a COX-2 selective anti-inflammatory approved by the U.S. Food and Drug Administration on 20 May 1999 and marketed as a gentler painkiller that spared the stomach, was instead associated with one of the largest drug-safety catastrophes in regulatory history. FDA drug-safety reviewer David Graham would testify to the Senate Finance Committee on 18 November 2004 that the drug had caused on the order of 88,000 to 139,000 excess heart attacks and strokes in the United States, of which perhaps 30 to 40 percent were fatal — a toll he compared to between two and four jumbo-jet crashes a week sustained over five years.
The gap between promise and reality was not discovered late; it was visible in Merck’s own trials. The VIGOR study, published in The New England Journal of Medicine on 23 November 2000 under lead author Claire Bombardier, showed that the 8,076 patients taking rofecoxib had roughly four to five times the rate of myocardial infarction of patients taking the older drug naproxen — a relative risk the published paper reported as 0.2 in naproxen’s favor. Merck attributed the difference to a supposed protective effect of naproxen rather than a cardiac hazard of Vioxx — a hypothesis that was never proven and that the company continued to advance while sales climbed past $2.5 billion a year and a sales force of more than 3,000 representatives carried the message to prescribers.
The withdrawal came only when the harm became impossible to explain away. The APPROVe trial — designed to test whether Vioxx prevented recurrent colon polyps, not to study the heart — was halted early on 23 September 2004 after showing that rofecoxib roughly doubled the risk of confirmed cardiovascular events after eighteen months of use, against placebo. The verdict here is therefore plain at the outset: an approved, heavily advertised, trusted medicine reached tens of millions of patients while the signal that would eventually condemn it sat in the company’s data, the FDA’s review files, and the medical literature, fully legible to anyone with access and the will to read it.
What followed was the largest pharmaceutical mass-tort reckoning of its era. In November 2007 Merck agreed to pay $4.85 billion to resolve roughly 27,000 lawsuits covering some 47,000 plaintiff groups, NEJM issued a formal “Expression of Concern” alleging the VIGOR authors had withheld cardiac data, and the case became the standard byword for how surrogate-endpoint approval, aggressive marketing, and suppressed safety signals can converge into mass harm before any regulator pulls the cord.
When Pfizer pulled Bextra from the U.S. market on 7 April 2005 — not voluntarily, but at the written request of the U.S. Food and Drug Administration — the company described a balanced judgment about risks and benefits; the documented record shows a drug whose dangers had been measurable for at least a year and whose marketing had outrun every safety signal it generated. Bextra (valdecoxib), a COX-2 selective anti-inflammatory developed by G. D. Searle/Pharmacia and co-promoted by Pfizer after approval on 20 November 2001 for osteoarthritis, rheumatoid arthritis, and menstrual pain, was withdrawn for two converging harms: an excess of heart attacks and strokes, and a rare but lethal class of skin reactions. The FDA concluded the drug offered no demonstrated advantage over existing NSAIDs to justify either.
The cardiovascular signal was not theoretical. A randomized trial in 1,671 cardiac-surgery patients — Nussmeier et al., published in The New England Journal of Medicine on 17 March 2005 — found that patients given parecoxib followed by valdecoxib after coronary-artery-bypass-graft surgery suffered cardiovascular events at a risk ratio of 3.7 (95% confidence interval 1.0–13.5; P=0.03), roughly 2.0 percent versus 0.5 percent on placebo. This was the same COX-2 hazard that had condemned Vioxx six months earlier, surfacing in Pfizer’s own franchise.
The dermatologic harm was, if anything, more distinctive. Because valdecoxib is a sulfonamide, it carried a strong association with Stevens-Johnson syndrome and toxic epidermal necrolysis — conditions in which the skin blisters and sloughs and which kill a meaningful fraction of those who develop them. By the end of March 2004 the FDA had logged on the order of 63 reported cases of SJS/TEN tied to the drug, several of them fatal. In mid-October 2004, Pfizer sent physicians a warning letter; a boxed warning followed; the withdrawal followed that. The verdict is therefore plain at the outset: a me-too painkiller with no proven edge over cheap generics was kept on the market and aggressively promoted while it accumulated both a cardiac body count and a roster of fatal skin reactions — and the reckoning, when it came, took the form of the largest health-care fraud prosecution the Justice Department had ever brought.
When Wyeth-Ayerst Laboratories pulled Duract from American pharmacies on 22 June 1998, the company cast it as a precaution against rare liver events in patients who had overstayed a clearly printed 10-day limit; the documented record shows the hepatic hazard was visible inside the drug’s own approval file nearly a year earlier, and that an FDA medical officer had argued — and lost — for a boxed warning before a single prescription was written. Duract (bromfenac sodium), a short-term non-steroidal anti-inflammatory approved by the U.S. Food and Drug Administration on 15 July 1997 for acute pain lasting ten days or less, instead became one of the fastest market withdrawals of the modern era. In roughly eleven months it generated some 2.5 million prescriptions and was associated with at least four deaths and eight liver transplants from fulminant hepatic failure, plus a further dozen serious liver injuries, with the count of severe drug-induced liver injury cases ultimately climbing past fifty.
The gap between promise and harm was not a post-market surprise. Bromfenac’s submission already showed that roughly 15 percent of short-term trial patients developed elevations of the liver enzymes AST or ALT to three times the upper limit of normal — a signal of hepatocellular stress markedly greater than that seen with comparable NSAIDs. The FDA medical reviewer who read that data advocated a black-box warning as a condition of approval and was overruled; the drug shipped instead with a routine label and a duration cap of ten days, on the theory that limiting exposure would contain the risk.
That theory collapsed against ordinary prescribing behavior. Acute pain frequently does not resolve in ten days, refills were written, and patients took bromfenac for weeks. The cases that killed and transplanted clustered almost entirely in this extended-use population — the precise scenario the 10-day rule was meant to prevent but had no mechanism to enforce. The verdict here is therefore plain at the outset: an approved, branded analgesic reached millions while the hepatotoxic signal that would condemn it sat fully legible in the agency’s own pre-approval review.
What followed was a rapid, near-total revocation. Wyeth strengthened the warnings in February 1998, the harm continued, and the company withdrew the drug in June; the FDA later formally rescinded the New Drug Application. The molecule survived only by abandoning the bloodstream — reformulated years later as a topical eye drop, where systemic exposure was negligible — while “Duract” became a byword for a withdrawal whose justification had been written before the launch.